significant difference in clinical endpoints. 7 In the recently published Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) trial, a guided de-escalation strategy from prasugrel to clopidogrel after an acute coronary syndrome (ACS), monitored by a platelet reactivity test, was non-inferior to conventional strategy with prasugrel. 8 Given the uncertainty of evidence and the high cost of the alternative agents to clopidogrel and the cost of the platelet reactivity tests, local cost-effectiveness analyses are necessary before widely adopting these strategies. In the current edition of European Cardiology Review, a simulated analysis of DAPT post-ACS driven by testing for platelet reactivity gives some hope that a personalised approach to anti-platelet therapy is still worth exploring. 9 We believe that the randomised trial evidence mentioned above is too convincing to resurrect this approach. p=0.002 for the presence of two LOF alleles). 10 In the Platelet Inhibition and Patient Outcomes (PLATO) genetic sub-study, which included slightly more than half of the 18,624 patients from the original trial, a trend was observed for reduced cardiovascular outcomes in patients with a CYP2C19 LOF allele treated with ticagrelor compared with clopidogrel, although no formal interaction was observed in this subgroup (p for interaction 0.46). 11 In a multicentre non-randomised study published last year, patients with a LOF CYP2C19 allele prescribed clopidogrel had a higher risk of cardiovascular events compared to patients treated with other agents (HR 2.26%; 95% CI [1.18 to 4.32]; p=0.013). 12 
Additionally, the Pharmacogenetics of Clopidogrel in Patients with
Acute Coronary Syndromes (PHARMCLO) trial was stopped recently due to issues concerning the certification of the genotyping test in use.
Despite being prone to bias, the partial results for approximately one- Personalised Approaches to Improving the Effect of Anti-platelet Agents:
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